MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.
MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world's largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease - to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.
"The latest research - such as The Cancer Genome Atlas funded by the NIH - demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes. The MediSapiens software gives personalized and clinically applicable insight into each patient's cancer," says Tommi Pisto, CEO and Co-founder of MediSapiens.
"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer. Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients," comments Professor Olli Kallioniemi, MediSapiens board member and director of the Institute for Molecular Medicine Finland (FIMM).
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation